Clinical trials
Renal Transplant Rejection clinical trials
Below are recruiting renal transplant rejection clinical trials, each written for real people, not researchers. We’re tracking 40 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07508787RecruitingPhase 2
Study comparing siplizumab to another drug for kidney transplant acceptance
This trial tests a new drug, siplizumab, to see if it helps the body accept a donated kidney better than a standard treatment. It is for people receiving a kidney transplant from a living or deceased donor.
Sacramento, CaliforniaAges 18–70 - NCT06025240Recruiting
Better antibody monitoring after kidney transplant
This study tests a new way to monitor harmful antibodies after a kidney transplant. It may help prevent transplant rejection over time.
Liverpool, MerseysideAges 18 years+ - NCT05600634Recruiting
Monitoring skin graft to spot rejection after kidney transplant
This study follows people after a kidney transplant to see if a small skin graft can help detect early signs of acute rejection. It may help your care team notice rejection sooner and adjust treatment earlier.
Xi'an, ShannxiAges 18–60 - NCT05084768Recruiting
Test blood markers to predict kidney transplant rejection
This study looks at special blood tests to help predict when kidney transplant rejection might happen. If the markers work, they could help doctors catch rejection earlier and adjust treatment sooner.
Loma Linda, CaliforniaAges 18 years+ - NCT06474273RecruitingPhase 3
Treating T-cell rejection after kidney transplant
This trial tests a new approach to treat T-cell mediated rejection in kidney transplant recipients. It aims to safely and effectively stop the rejection episode.
Lambton, New South WalesAges 2 years+ - NCT03707262RecruitingPhase 1/Phase 2
Brother or sister donor transplant using kidney and stem cells
This study tests a combined approach for kidney transplant patients: standard living-donor kidney transplant plus an added “stem cell” component taken from the same sibling donor. It aims to improve transplant outcomes by trying to better control the immune response and reduce complications.
Los Angeles, CaliforniaAges 18 years+ - NCT07053462RecruitingPhase 1/Phase 2
Gene-edited kidney transplant to lower rejection risk
This trial tests a specially edited donor kidney designed to reduce the chance of rejection, especially for people with high sensitivity to donor kidneys. If it works, it could make more kidneys available for those who have a hard time finding a match.
Beijing, ChangpingAges 16–85 - NCT07531966Recruiting
Blood Vessel Problems After Kidney Transplant Treatment
This study looks at treating narrowing or blockage of blood vessels in transplanted kidneys. If your transplanted kidney is showing signs of not working well and imaging shows a blocked vessel, this trial tests whether a procedure called angioplasty (opening the vessel with a tiny balloon) can help restore blood flow and improve kidney function.
AarhusAges 18 years+ - NCT03994497Recruiting
Testing a blood marker to predict rejection after kidney transplant
This study looks at a specific marker on immune cells (called CD45RC on T lymphocytes) to see if it can predict when a kidney transplant might reject. If you’re at lower immunologic risk, your blood tests could help doctors spot rejection risk earlier.
AngersAges 18–70 - NCT05702931RecruitingPhase 4
Semaglutide for high blood sugar after kidney transplant
This trial tests semaglutide, a medicine that helps lower blood sugar, in people who develop high blood sugar shortly after a kidney transplant. It may help control blood sugar without harming the transplanted kidney, while also checking safety in this specific group.
CopenhagenAges 18–80 - NCT05385432RecruitingPhase 3
Kidney transplant induction therapy for sensitized patients
This trial tests a specific “induction” treatment to help people who have stronger immune reactions from past sensitizing events during a kidney transplant. It may help improve how well the transplant works and how safely the immune system is managed.
ToursAges 18–79 - NCT06910527Recruiting
Testing blood and urine for kidney rejection signs
This study is for people with a kidney transplant who are in the hospital for a biopsy because their doctor suspects rejection. Researchers want to see if a simple blood or urine test can detect rejection, which might make future biopsies less necessary.
RouenAges 18 years+ - NCT06751602Enrolling by invitationPhase 2
Belumosudil to prevent kidney scarring after transplant
This trial tests whether a drug called belumosudil can reduce scarring in the kidney after transplant. Scarring can lead to kidney damage over time, and this study aims to stop that from happening.
Houston, TexasAges 18–75 - NCT07046910RecruitingPhase 2
MRI to detect lung rejection after transplant
This study uses a special MRI scan (called hyperpolarized gas MRI) to check for signs of lung rejection after a transplant. The goal is to see if the MRI can help detect rejection earlier and more safely than standard bronchoscopy alone.
Charlottesville, VirginiaAges 18–80 - NCT06406179Recruiting
Blood test for donor DNA in kidney transplant care
This trial is testing whether a simple blood test that looks for donor DNA can help doctors take better care of kidney transplant patients. It may help detect early signs of rejection and guide treatment decisions.
ParisAges 18 years+ - NCT06400771RecruitingPhase 1
Safety of DNP007 in Healthy Volunteers
This study tests the safety of a new drug called DNP007 in healthy volunteers. It is a Phase 1 trial, meaning it's one of the first steps in humans to see if the drug is safe and how the body handles it.
SeoulAges 19–55 - NCT06830473Recruiting
Study on predicting kidney transplant rejection in Scotland
This study looks at whether certain tests can help predict or diagnose kidney transplant rejection. If you have had a kidney transplant and are being followed at a main transplant centre in Scotland, you may be able to take part by giving urine samples during your regular check-ups.
EdinburghAges 18–99 - NCT07134491Recruiting
B Cells in Kidney Transplant Rejection Study
This study looks at certain immune cells (B cells) in the blood and kidney to better understand antibody-mediated rejection in kidney transplant patients. It might help doctors find new ways to diagnose or treat this type of rejection.
ParisAges 18 years+ - NCT06997471RecruitingPhase 1
Safety of modified stem cell infusion with organ transplant
This early-phase trial tests whether it is safe to give a special type of stem cell transplant (with the naïve T cells removed and only memory T cells left) to people receiving organ transplants. It is for children getting intestine or lung transplants, and for children or adults getting kidney transplants.
Madrid, MadridAges birth+ - NCT04450953RecruitingPhase 3
Eplerenone to slow blood vessel damage after kidney transplant
This trial tests whether eplerenone can slow the progression of blood vessel (vasculature) problems in people who have had a kidney transplant. You may be eligible if you are older, stable on your transplant medicines, and have higher peripheral artery blood pressure readings.
Vandœuvre-lès-NancyAges 50 years+ - NCT05655273Enrolling by invitationPhase 4
Switch tacrolimus timing after liver transplant to Envarsus
This trial looks at whether changing your maintenance anti-rejection medicine from Prograf (usually twice daily) to Envarsus (once daily) can help keep your liver and kidney function stable. It targets people who may be having kidney side effects, symptoms from tacrolimus, or trouble taking a twice-daily medicine.
Toronto, OntarioAges 18–99 - NCT05788276RecruitingPhase 4
Dapagliflozin to help transplanted kidneys stay healthy
This study tests whether dapagliflozin can preserve the structure and function of a kidney transplant. You may be asked to take dapagliflozin on top of usual transplant medicines to see if it helps the new kidney work better over time.
Oslo, OsloAges 18–75 - NCT07663669Recruiting
Photopheresis for antibody-mediated rejection in kidney transplant
This study looks at how well extracorporeal photopheresis (a treatment that filters and treats your blood with light) works for kidney transplant patients who have antibody-mediated rejection (when your immune system attacks the new kidney). It may help doctors understand if this treatment can stop the rejection.
BesançonAges 18 years+ - NCT01531257Recruiting
Monitoring genes and health after kidney transplant
This study follows people who are getting a kidney transplant (first or later) to better understand how the body recovers, using health tracking and “gene/protein” (proteogenomic) information. It may help doctors predict complications and improve care after transplant.
Chicago, IllinoisAges 18 years+
Hear when a new Renal Transplant Rejection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for renal transplant rejection?
- Yes. Clin2 currently lists 40 recruiting renal transplant rejection studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a renal transplant rejection trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a renal transplant rejection trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.